Our invention boasts its feasibilityvalue in a non-invasive, etiological diagnosis for IgA nephropathy (IgAN), by: (1) an IgAN specific real-time PCR assay (2) Applied Biosystems TaqMan assay 24-384-well TaqMan Array cards (microfluidic cards)(3) Digital PCR assay. These newly developed knowhow-based steps serve as a well-documented example for most of the other autoimmune diseases in generating etiological, non-invasive diagnostic reagents.

To develop non-invasive measures for etiological, early diagnosis of IgA nephropathy (IgAN) is clinicallyurgently warranted. To do this, we have been successful in demonstrating for the first time a set of IgG autoantibodies against IgA1 autoantigensthereby established the following diagnostic tests: (1) an IgAN specific real-time PCR (2) Applied Biosystems assay 24-384-well TaqMan Array cards (microfluidic cards)(3) Digital PCR assay.

Our invention with the following tests: (1) an IgAN specific real-time PCR assay (2) Applied Biosystems TaqMan assay 24-384-well TaqMan Array cards (microfluidic cards)(3) Digital PCR assay. These newly developed knowhow-based steps will be able to serve as well-documented examples for most of other autoimmune diseases in especially generating etiological, non-invasive diagnostic reagents. Our estimated benefits as follows: Domestic – NT$460 million Global - NT$20 billion.